Britain's publicly funded "invention agency" has directed more than an eighth of its research budget to American technology companies and venture capital groups, raising questions about whether taxpayer money is delivering benefits for the UK economy.
The Advanced Research and Invention Agency (Aria), established to fund ambitious scientific projects and restore Britain's standing as a scientific superpower, has allocated £50m of UK taxpayer money to 14 US tech companies and venture capital projects over the past two years, according to a joint investigation by the Guardian and Democracy for Sale.
In some cases, the grants appear to lack clear returns for the UK or Aria itself. The agency has spent £23m on nine US tech firms and awarded an additional £6m to Normal Computing, which established its UK presence only weeks before receiving the grant. It has also distributed £29.4m to three US venture capital groups tasked with supporting early-stage UK tech talent.
The Scale of Overseas Spending
Aria's total research and development funding stands at £400m over the past two years. The £50m directed to US firms and venture capital groups represents a significant portion of this public investment, raising concerns about whether the agency is meeting its statutory obligations to benefit the UK.
Among the funded companies is the CIC Venture Cafe Global Institute, a US business hosting entrepreneur events, which received £5.4m to operate "venture cafes" across the UK. The US firm Fifty Years secured £7m to run a 14-week course teaching scientists how to start companies—a course it will deliver six times to 50 students each.
Pillar VC incorporated in the UK one day before Aria awarded it a £10.9m contract. Renaissance Philanthropy, backed by former Google CEO Eric Schmidt, incorporated in the UK shortly before receiving £13.3m from Aria. The timing of these incorporations has raised questions about whether the UK presence represents genuine commitment or a contractual formality.
Accountability and Transparency Gaps
Chi Onwurah, chair of the Commons science and technology committee, has called for stronger scrutiny of Aria's spending decisions. "These reports on Aria's spending underline the need for stronger scrutiny of the organisation, something its chair acknowledged when he appeared in front of my committee in 2025," Onwurah said.
Onwurah highlighted a fundamental concern: "The Aria Act requires the organisation to benefit the UK by driving economic growth, supporting scientific innovation or improving quality of life. It's unclear how funding US-based venture capital and tech firms meets these aims, or aligns with the government's commitment to regional innovation."
The agency's regional distribution of funds compounds these concerns. Aria allocates only a small share of its funding outside London and the south-east, with the West Midlands receiving just 0.8% of grants. This concentration of investment in already-prosperous regions contradicts stated government commitments to reducing regional inequality.
Aria was controversially exempted from freedom of information laws when established, and for its first years of operation, it published no details about its grantees. The agency remains unclear about whether it has strict guidelines limiting how much funding can go to non-UK businesses.
The Broader Pattern
Cecilia Rikap, an economics professor at University College London, argues the grants reflect a troubling dynamic: "Disguised as promoting moonshot projects, the government is using taxpayer money to further expand the power of the US tech ecosystem. This is not a surprise coming from a government that has agreed to be not only Trump's, but also big tech's, footman."
Rikap contends that US tech companies function as "intellectual monopolies that present themselves as contributing to public knowledge, all the while finding ways to monetise it." She notes that "data and knowledge are co-produced with universities and local companies but always following the priorities of big tech, so that whatever new research is developed, it remains within the platforms and ecosystems that they control."
Several US companies funded by Aria appear to be early-stage ventures already backed by powerful US investors. MorphoAI, for instance, has support from Y Combinator, while Sangtera benefits from backing by the US National Science Foundation.
Aria has defended its spending, stating that over 80% of its funding goes to UK-based teams and that international grants are designed to "transfer scientific capabilities to the UK, with contractual protections ensuring the benefits flow back here." The agency said it does not typically take shares or intellectual property rights in funded companies, but requires royalty fees on any IP commercialised outside the UK.
However, the case of Rain Neuromorphics—backed by OpenAI chief executive Sam Altman and reported to be near collapse last year shortly after winning Aria funding—illustrates the risks of this hands-off approach. The company did not respond to requests for comment, and two of its founders appear to have left.
Normal Computing argued that establishing a UK presence was a contractual requirement and claimed to have reinvested approximately 150% of its award value back into the UK through salaries and operations. Fifty Years said UK scientists would benefit from its programme but could not have brought it to the country without Aria's support, noting it has funded two companies emerging from its UK programme.
Why This Matters:
Public investment in scientific research represents a collective commitment by taxpayers to build national capability and economic resilience. When substantial portions of this investment flow to foreign companies—particularly those already backed by major US venture capital and tech firms—it raises fundamental questions about whether public resources are being deployed to strengthen the UK economy or to further entrench the dominance of existing US tech ecosystems. The lack of transparency about how much funding goes overseas, combined with regional concentration of grants in already-wealthy areas, suggests systemic accountability gaps. For communities outside London and the south-east, and for UK-based innovators competing against well-funded US rivals, these spending patterns have real consequences for opportunity and economic distribution.